Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Pharma-Bio Serv's operating income for the twelve months ending Jul 31, 2026 was -$154.94K. For fiscal 2025 it was -$637.66K. The highest annual figure on record is $6.07M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$637.66K | – |
| FY2024 | Oct 31, 2024 | -$1.29M | -215.2% |
| FY2023 | Oct 31, 2023 | $1.12M | -4.9% |
| FY2022 | Oct 31, 2022 | $1.17M | – |
| FY2021 | Oct 31, 2021 | -$3.85M | -273.2% |
| FY2020 | Oct 31, 2020 | $2.23M | +31.2% |
| FY2019 | Oct 31, 2019 | $1.70M | – |
| FY2018 | Oct 31, 2018 | -$1.26M | – |
| FY2017 | Oct 31, 2017 | -$777.82K | – |
| FY2016 | Oct 31, 2016 | -$91.76K | -105.2% |
| FY2015 | Oct 31, 2015 | $1.78M | -37.8% |
| FY2014 | Oct 31, 2014 | $2.86M | -52.8% |
| FY2013 | Oct 31, 2013 | $6.07M | +5.9% |
| FY2012 | Oct 31, 2012 | $5.73M | +66.1% |
| FY2011 | Oct 31, 2011 | $3.45M | +466.0% |
| FY2010 | Oct 31, 2010 | $609.89K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$71.81K | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $144.68K | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$94.54K | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$133.27K | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$313.88K | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$98.32K | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$92.19K | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$154.13K | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$381.78K | -182.9% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$313.38K | -182.5% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$438.30K | -233.4% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$51.77K | -105.1% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $460.47K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $380.08K | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $328.63K | -8.8% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $1.01M | +279.9% |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$369.51K | -215.8% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$4.80M | -3262.6% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $360.49K | -55.9% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $264.78K | -63.2% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $319.12K | -40.5% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $151.71K | -64.4% |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $816.69K | +126.4% |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | $720.38K | +51.0% |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $536.76K | +14.0% |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $426.56K | -14.2% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $360.70K | -50.0% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $476.93K | – |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | $471.02K | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $497.44K | +298.0% |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $721.82K | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$8.68K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$2.47M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | $125.00K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$194.25K | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$324.57K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$384.00K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$449.76K | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -$120.79K | – |
See a number that looks wrong?